Trump Pauses Disbursement of Global HIV Treatment Funds
By Stephanie Brown HealthDay Reporter
MONDAY, Jan. 27, 2025 -- The Trump administration has paused funding for a crucial HIV treatment program in Africa and developing countries for 90 days, according to a memo obtained by The New York Times.
The directive stems from President Trump's executive order on foreign aid, in which all government divisions with foreign development assistance programs have been ordered to stop disbursing funds. Initial review of foreign aid is intended to be completed within 85 days; however, final decisions might take up to 180 days.
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), a $7.5 billion program under the governance of the State Department, was due for a five-year reauthorization in 2023. After avoiding a Republican effort to end the program, it was renewed for one year, according to The Times.
Many public health and development experts are dismayed at this hold on funding.
"Any prolonged pause in funding could disrupt HIV treatment programs, leading to treatment interruptions, rise of drug-resistant HIV," Jirair Ratevosian, Ph.D., who served as chief of staff for PEPFAR during the Biden administration, told The Times. "That's playing with fire, risking progress that we've made over decades to control the HIV epidemic." Ratevosian added that resistant strains of the virus that may emerge in other nations would also be of great concern to Americans.
The New York Times Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-28 06:00
Read more
- How do GLP-1s Boost Weight Loss, Heart Health?
- Multilingual Children with Autism Show Improved Cognitive Function
- Stimulant Dispensing to Children Decreased After Start of Pandemic, During Shortage
- Decrease Seen in In Situ Breast Cancer Since 2009
- FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease
- One in Four Older U.S. Veterans Report Cardiovascular Disease Diagnosis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions